8-K: SAB Biotherapeutics Appoints Interim CFO Following Departure of Michael King

SAB Biotherapeutics has appointed Mark Conley as Interim Chief Financial Officer, effective June 4, 2024, following the resignation of Michael King.

Summary

• SAB Biotherapeutics announced the resignation of its Chief Financial Officer, Michael King, effective June 4, 2024.
• Michael King is leaving to become CEO of a private oncology company but will remain an advisor to SAB through the end of the year.
• Mark Conley, the current Vice President of Finance, has been appointed as Interim Chief Financial Officer, also effective June 4, 2024.
• Conley has 38 years of experience in biotech finance and accounting.
• The company has launched a formal search for a permanent CFO.
• Conley's compensation will remain the same as per his existing employment agreement, which includes a $303,000 annual base salary and a potential 43% bonus.
• Conley also has options to acquire 250,000 shares of the company's common stock, vesting over four years.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there is a change in leadership, the company has a plan in place with an interim CFO and a search for a permanent replacement. The company also reaffirmed its outlook for 2024.

Positives

• The company has a ready replacement in Mark Conley, who is already familiar with the company's operations.
• Michael King will remain as an advisor to the company through the end of the year, ensuring a smooth transition.
• The company has confirmed its outlook for fiscal year 2024 and upcoming milestones, including a topline data readout from its Phase 1 study of SAB-142.

Negatives

• The departure of the CFO, Michael King, could create some uncertainty in the short term.
• The company will need to dedicate resources to the search for a permanent CFO.

Risks

• The transition to a new CFO, even on an interim basis, could pose operational risks.
• The search for a permanent CFO could take time and resources.
• The company's future performance is subject to risks and uncertainties, as detailed in their SEC filings.

Future Outlook

The company confirmed its outlook for fiscal year 2024 and its upcoming milestones, including a topline data readout from its Phase 1 study of SAB-142.

Management Comments

• Samuel J. Reich, Chairman and CEO, stated that Mike has been an outstanding partner and wished him the best in his next role.
• Samuel J. Reich expressed optimism about the future of SAB as they continue expanding their clinical program.
• Michael King thanked SAB, its board and employees for the opportunity to work together and looks forward to his role as an advisor.
• Michael King stated he holds SAB's mission in high regard and looks forward to charting the company's success.

Industry Context

The departure of a CFO is not uncommon in the biotech industry, especially when executives are offered CEO positions at other companies. The appointment of an interim CFO from within the company is a common practice to ensure continuity while a permanent replacement is sought.

Comparison to Industry Standards

• The compensation package for the interim CFO, including a base salary of $303,000 and a potential 43% bonus, is within the typical range for a company of this size and stage in the biotech industry.
• The vesting schedule for the stock options, with 25% vesting after one year and the remaining 75% vesting monthly over three years, is a standard practice in the industry.
• The appointment of an interim CFO while conducting a search for a permanent replacement is a common practice among publicly traded companies, including those in the biotech sector. Companies such as Amgen, Biogen, and Gilead have all gone through similar transitions.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the CFO transition, but the company's reaffirmation of its outlook should provide some reassurance.
• Employees may experience some change with the new interim CFO, but the company's operations are expected to continue as normal.
• Customers and suppliers are not expected to be significantly impacted by this change.

Next Steps

• The company will conduct a formal search for a permanent Chief Financial Officer.
• The company will continue its clinical program for SAB-142 and anticipates a topline data readout from its Phase 1 study.
• Michael King will transition into an advisory role through the end of the year.

Key Dates

Keywords

CFO, Chief Financial Officer, Interim CFO, executive change, biotechnology, SAB Biotherapeutics, finance, management, Mark Conley, Michael King